Compositions and methods for binding agglomeration proteins

Details Compositions and methods for binding agglomeration proteins Compositions and methods for binding agglomeration proteins

2007-06-19

2007-06-19

Campell, Bruce R. (Department: 1648)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S025600, C536S023100, C977S704000

Reexamination Certificate

active

11112953

ABSTRACT:
Amplibody compositions and methods used to interact with agglomeration proteins are disclosed herein. Compositions herein comprise one or more DNA or RNA molecules having affinity for at least one agglomeration protein. The nucleic acid component is a naturally or non-naturally occuring molecule with twenty or more ribonucleotide bases. For RNA, at least one nucleotide sequence portion of this RNA molecule has affinity to at least one consensus sequence present in the agglomeration RNA-binding protein. The portion of nucleotide sequence of RNA having affinity for agglomeration proteins is a sequence that is derived from either and RNA virus, and RNA agglomeration proteins is a sequence that is derived from either and RNA virus, an RNA phage, a messenger RNA (“mRNA”), a ribosomal RNA (“rRNA), a transfer RNA (“tRNA”), a sequence that is received as a template by one or more RNA dependent RNA polymerases, or a combination thereof. Methods disclosed herein are directed towards detecting the presence of one or more agglomeration proteins in a sample matrix using the amplibody compositions described herein.

REFERENCES:
patent: 5876930 (1999-03-01), Livak et al.
patent: 5932711 (1999-08-01), Boles et al.
patent: 6225058 (2001-05-01), Munishkin et al.
patent: 6426409 (2002-07-01), Winnacker et al.
patent: 6916613 (2005-07-01), Munishkin et al.
patent: 2002/0197737 (2002-12-01), Mandelkow et al.
patent: 2004/0005543 (2004-01-01), Grossman et al.
patent: 2005/0261486 (2005-11-01), Grossman et al.
patent: 2005/0266401 (2005-12-01), Grossman et al.
patent: 2005/0266402 (2005-12-01), Grossman et al.
patent: 8809810 (1988-12-01), None
patent: 8910134 (1989-11-01), None
patent: 9715685 (1997-05-01), None
Weiss et al., RNA Aptamers Specifically Interact With the Prion Protein PrP; J. Of Virology, Nov. 1997, vol. 71, No. 11, pp. 8790-8797.
Holeman et al., Isolation and Characterization of Fluorophore-Binding RNA Aptamers, Folding and Design; Oct. 30, 1998, vol. 3, No. 6, pp. 423-431.
Shi et al., RNA Aptamers as Effective Protein Antagonists in a Multicellular organism; Proceedings of the National Academy of Science USA, Aug. 1999, vol. 96, No. 18, pp. 10033-10038.
Scheffer et al., Interaction of 68-kDa TAR RNA-Binding Protein and other Cellular Proteins with Prion Protein—RNA Stem Loop; Neurovirol, 1995 vol. 1, pp. 391-398.
Battle and Doudna, “The Stem-loop Binding Protein Forms a Highly Stable and Specific Complex with the 3′ Stem-loop of Histone Mrna,” 2001 RNA 7:123-32.
Carp et al., “Scrapie Strain-specific Interactions with Endogenous Murine Leukamia Virus,” 1999 J Gen Virol 80(Pt 1):5-10.
Cordeiro et. al., “Dna Converts Cellular Prion Protein into the β-sheet Conformation and Inhibits Prion Peptide Aggregation,” 2001 J Biol Chem 276(52):49400-9.
Endo and Wool, “The Site of Action of A-sarcin on Eucariotic Ribosomes,” 1982, J. Biol. Chem. 257(15):9054-60.
Gabus et al., “The Prion Protein Has RNA Binding and Chaperoning Properties Characteristic of Nucleocapsid Protein Nc P7 of HIV-1,” 2001b J Biol Chem 276(22):19301-9.
Jiang et al., “Anchoring and Extended HTLV-1 Rex peptide within an RNA Major Groove Containing Junctional Base Triples,” 1999 Structure Fold Des. 7(12):1461-72.
Letsinger et al., “Cholesteryl-conjugated Oligonucleotides: Synthesis, Properties, and Activity as Inhibitors of Replication of Human Immunodeficiency Virus in Cell Culture,” (1989) Proc. Natl. Acad. Sci. USA 86:6553-6556.
Lemaitre et al., “Specific Antiviral Activity of a Poly(L-Lysine)-conjugated Oligodeoxyribonucleotide Sequence Complimentary to Vesticular Somatitis Virus N Protein mRNA initiation site,” (1987) Proc. Natl. Acad. Sci. USA 84:648-652.
Lochrie et. al., “In vitro selection of RNAs that bind to the human immunodeficiency virus type-1 gag polyprotein,” 1997 NAR 25(14):2902-10.
Meyer et. al., “A Monomer-Dimer Equilibrium of a Cellular Prion Protein (PrPc) Not Observed with Recombinant PrP,” 2000, J Biol Chem Dec. 1, 275(48):38081-7.
Murdoch, et al., “Potential Retroviral RNA's in Creutzfeldt-Jakob Disease,” 1990 Virology 64(4):1477-86.
Munishkin et. al., “Efficient Templates for Qβ Replicase are Formed by Recombination from Heterologous Sequences,” 1991, J Mol Bio 221(2):463-72.
Narang, “A Critical Review of the Nature of the Spongiform Encephalopathy Agent: Protein Theory Versus Virus Theory,” 1998 Res Virol 149(6):375-82.
Pan et al., “Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins,” 1993 PNAS, USA 90:10962-66.
Zeiler et. al, “Improved Approach to RNA and Protein Recognition for Pathogen Detection,” 2000, Proceedings of SPIE Aerosense 2000, 4036:103-14.
Gabus et al., “The Prion Protein Has RNA Binding and Chaperoning Properties Characteristic of Nucleocapsid Protein NCp7 of HIV-1,” The Journal of Biological Chemistry, vol. 276, No. 22, pp. 19301-19309, Jun. 1, 2001.
Goeddel; “Systems for Heterologous Gene Expression,” Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif., pp. 3-7, (1990).
Gottesman, S., “Minimizing Proteolysis inEscherichia coli: Genetic Solutions,” Gene Expression Technology: Methods in Enzymology 185, Academic Press, San Diego, Calif.; pp. 119-128 (1990).
Akowitz et al., “Endogenous Viral Complexes with Long RNA Cosediment with the Agent of Creutzfeldt-Jakob Disease,” Nucleic Acids Research, 1994, vol. 22, No. 6, pp. 1101-1107.
Amann et al., “Tightly RegulatedtacPromoter Vectors Useful for the Expression of Unfused and Fused Proteins inEscherichia Coli,” Gene 69 (1988), pp. 301-315.
Hegde et al., “A Transmembrane Form of the Prion Protein in Neurogenerative Disease,” 1998 Science 279(5352):827-34.
Hermann and Westhof, “Non-Watson-Crick base pairs in RNA-protein Recognition,” 1999 Chem Biol 6(12)-R335-43.
Hermann and Patel, “Adaptive Recognition by Nucleic Acid Aptamers,” 2000 Science 287(5454):820-5.
Iwai et al., “Recognition of the High Affinity Binding Site in Rev-response Element RNA by the Human Immunodeficiency Virus Type-1 rev Proten,” 1992, Nucleic Acid Research 20(24):6465-72.
Chesebro et al., “Identification of Scrapie Prion Protein-Specific mRNA in Scrapie-Infected and Uninfected Brain,” Nature vol. 315, pp. 331-333, May 23, 1985.
Current Protocols in Molecular Biology, John Wiley & Sons, NY (1989); Sections 6.3.1-6.3.6.
Nandi, Polymerization of Human Prion Peptide HuPrP 106-126 to Amyloid In Nucleic Acid Solution, 1998 Arch Virol 143(7):1251-63.
Nandi and Leclerc, “Polymerization of Murine Recombinant Prion Protein in Nucleic Acid Solution,” 1999 Arch Virol 144(9):1751-63.
Nandi and Sizaret,“Murine Recombinant Prion Protein Induces Ordered Aggregation of Linear Nucleic Acids to Condensed Globular Structures,” 2001 Arch Virol 146:32745.
Narang, “Evidence That Single-stranded DNA Wrapped Around the Tubulofilamentous Particles Termed “Nemaviruses” is the Genome of the Scrapie Agent,” Res. Virol. 1998, 149, pp. 375-382.
Oesch et al., “A Cellular Gene Encodes Scrapie PrP 27-30 Protein,” 1985 Cell 40:735-46.
Patel, “Adaptive Recognition in RNA Complexes with Peptides and Protein Modules,” 1999 Curr Opin Struct Biol 9(1):74-87.
Preuβ et al., “Probing RNA-Protein Interactions Using Pyrene-Labeled Oligodeoxynucleotides: Qβ Replicase Efficiently Binds Small RNAs by Recognizing Pyrimidine Residues,” 1997 J. Mol. Biol., Oct. 31, 273(3):600-13.
Puglisi and Williamson, “RNA Interaction with Small Ligands and Peptides,” 1999 in the RNA World, R F Gesteland, T R Cech, J F Atkins, eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 2d, 1999, pp. 403-4

Affiliated with

Also associated with

Rating

Compositions and methods for binding agglomeration proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for binding agglomeration proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for binding agglomeration proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3813311